Total Payments
$99,897
2024 Payments
$20,129
Companies
14
Transactions
85
Medicare Patients
1,390
Medicare Billing
$249,301
Payment Breakdown by Category
Consulting$83,193 (83.3%)
Research$7,837 (7.8%)
Travel$6,390 (6.4%)
Food & Beverage$2,477 (2.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $83,193 | 22 | 83.3% |
| Unspecified | $7,837 | 7 | 7.8% |
| Travel and Lodging | $6,390 | 25 | 6.4% |
| Food and Beverage | $2,477 | 31 | 2.5% |
Payments by Type
General
$92,060
78 transactions
Research
$7,837
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $43,887 | 23 | $0 (2023) |
| ABBVIE INC. | $11,812 | 10 | $0 (2024) |
| GlaxoSmithKline, LLC. | $9,750 | 4 | $0 (2022) |
| Celgene Corporation | $9,591 | 6 | $0 (2019) |
| Janssen Research & Development, LLC | $5,606 | 13 | $0 (2024) |
| Amgen Inc. | $5,374 | 8 | $0 (2018) |
| CSL Behring | $4,500 | 3 | $0 (2021) |
| Karyopharm Therapeutics Inc. | $4,453 | 5 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $2,595 | 1 | $0 (2024) |
| GENZYME CORPORATION | $719.00 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20,129 | 26 | ABBVIE INC. ($11,244) |
| 2023 | $4,923 | 10 | Takeda Pharmaceuticals U.S.A., Inc. ($4,200) |
| 2022 | $9,553 | 6 | GlaxoSmithKline, LLC. ($5,200) |
| 2021 | $9,422 | 8 | CSL Behring ($4,500) |
| 2020 | $12,815 | 7 | Takeda Pharmaceuticals U.S.A., Inc. ($8,465) |
| 2019 | $17,088 | 8 | Takeda Pharmaceuticals U.S.A., Inc. ($16,972) |
| 2018 | $19,582 | 15 | Takeda Pharmaceuticals U.S.A., Inc. ($10,459) |
| 2017 | $6,385 | 5 | Celgene Corporation ($5,725) |
All Payment Transactions
85 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/08/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $144.71 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Travel and Lodging | In-kind items and services | $867.59 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Travel and Lodging | In-kind items and services | $248.04 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Travel and Lodging | Cash or cash equivalent | $90.00 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Travel and Lodging | Cash or cash equivalent | $58.50 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Travel and Lodging | Cash or cash equivalent | $56.00 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Consulting Fee | Cash or cash equivalent | $4,050.00 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Travel and Lodging | Cash or cash equivalent | $70.00 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Food and Beverage | Cash or cash equivalent | $62.56 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Food and Beverage | In-kind items and services | $45.00 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Food and Beverage | Cash or cash equivalent | $14.17 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Food and Beverage | In-kind items and services | $13.69 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Food and Beverage | In-kind items and services | $12.65 | General |
| Category: Oncology | ||||||
| 08/28/2024 | Janssen Scientific Affairs, LLC | TALVEY (Biological) | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: Oncology | ||||||
| 07/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,595.00 | General |
| 04/07/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $30.51 | General |
| Category: Oncology | ||||||
| 04/05/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $96.48 | General |
| Category: CELLT | ||||||
| 04/05/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $61.38 | General |
| Category: Oncology | ||||||
| 04/04/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TALVEY, TECVAYLI | Food and Beverage | In-kind items and services | $127.24 | General |
| Category: Oncology | ||||||
| 04/04/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: Oncology | ||||||
| 04/03/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Oncology | ||||||
| 02/20/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $10,800.00 | General |
| 02/20/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $337.00 | General |
| 02/20/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $79.88 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3 Randomized Controlled, Open-Label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) | Karyopharm Therapeutics Inc. | $2,650 | 3 |
| 3300023 | Karyopharm Therapeutics Inc. | $1,750 | 1 |
| CC-5013-MM-020 | Celgene Corporation | $1,734 | 1 |
| A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY OF TAK-573 AS A SINGLE AGENT IN PATIENTS WITH REFRACTORY MULTIPLE MYELOMA | Takeda Pharmaceuticals U.S.A., Inc. | $1,200 | 1 |
| Phase 1 SA Safety-PK | Takeda Pharmaceuticals U.S.A., Inc. | $503.20 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 371 | 890 | $151,384 | $66,620 |
| 2022 | 6 | 318 | 699 | $106,327 | $53,507 |
| 2021 | 5 | 365 | 702 | $141,597 | $71,880 |
| 2020 | 6 | 336 | 674 | $147,350 | $57,294 |
Total Patients
1,390
Total Services
2,965
Medicare Billing
$249,301
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 170 | 504 | $83,487 | $38,251 | 45.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 80 | $17,705 | $7,903 | 44.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 96 | 154 | $14,322 | $7,727 | 54.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 25 | 48 | $11,088 | $3,710 | 33.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 28 | 31 | $8,332 | $3,444 | 41.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 49 | $9,924 | $3,218 | 32.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 11 | 11 | $4,927 | $1,655 | 33.6% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 12 | 13 | $1,599 | $711.88 | 44.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 163 | 472 | $66,215 | $36,236 | 54.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 68 | 97 | $9,021 | $4,968 | 55.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 30 | 59 | $13,754 | $4,477 | 32.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 29 | 37 | $8,140 | $4,225 | 51.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 17 | 17 | $6,035 | $2,523 | 41.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 17 | $3,162 | $1,079 | 34.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 141 | 375 | $82,500 | $44,400 | 53.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 135 | 198 | $27,850 | $16,075 | 57.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 56 | 96 | $22,551 | $7,412 | 32.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 21 | 21 | $7,455 | $3,320 | 44.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 12 | 12 | $1,241 | $673.16 | 54.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 159 | 412 | $91,005 | $36,821 | 40.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 35 | 49 | $16,765 | $5,542 | 33.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 15 | 60 | $10,560 | $5,340 | 50.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 36 | 41 | $9,471 | $2,810 | 29.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 45 | 50 | $6,275 | $2,230 | 35.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 13 | 29 | $3,799 | $1,785 | 47.0% |
About Dr. Dan Vogl, MD
Dr. Dan Vogl, MD is a Hematology & Oncology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1992733448.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dan Vogl, MD has received a total of $99,897 in payments from pharmaceutical and medical device companies, with $20,129 received in 2024. These payments were reported across 85 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($83,193).
As a Medicare-enrolled provider, Vogl has provided services to 1,390 Medicare beneficiaries, totaling 2,965 services with total Medicare billing of $249,301. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology
- Location Philadelphia, PA
- Active Since 06/30/2006
- Last Updated 02/01/2016
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1992733448
Products in Payments
- NINLARO (Drug) $27,588
- Revlimid (Drug) $9,475
- CARVYKTI (Drug) $5,606
- Kyprolis (Biological) $5,374
- BLENREP (Biological) $4,600
- XPOVIO (Drug) $4,453
- SARCLISA (Biological) $719.00
- DARZALEX (Biological) $704.66
- VENCLEXTA (Drug) $567.91
- TALVEY (Biological) $150.00
- Pomalyst (Drug) $115.68
- Yescarta (Drug) $96.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Philadelphia
Shayma Kazmi, Md, MD
Hematology & Oncology — Payments: $715,210
Hematology & Oncology $715,210
Charu Aggarwal, Md, Mph, MD, MPH
Hematology & Oncology — Payments: $510,275
Hematology & Oncology $510,275
Dr. Catherine Lai, M.d., M.p.h, M.D., M.P.H
Hematology & Oncology — Payments: $249,951
Hematology & Oncology $249,951
Dr. Martin Edelman, M.d, M.D
Hematology & Oncology — Payments: $207,464
Hematology & Oncology $207,464
Keith Pratz, M.d, M.D
Hematology & Oncology — Payments: $175,955
Hematology & Oncology $175,955
David Porter, Md, MD
Hematology & Oncology — Payments: $173,636
Hematology & Oncology $173,636